Adeno-associated virus (AAV) has emerged as a leading platform for gene delivery for
treating various diseases due to its excellent safety profile and efficient transduction to …

Introduction: The development of novel complex biotherapeutics led to new challenges in
biopharmaceutical industry. The potential of these particles has been demonstrated by the …

Gene therapy has demonstrated enormous potential for changing how we combat disease.
By directly engineering the genetic composition of cells, it provides a broad range of options …

Extracellular vesicles (EVs) have emerged as a novel cell-free strategy with broad
biomedical applications in disease diagnosis and prognosis as well as therapy. Moving EVs …

The COVID-19 pandemic has motivated the rapid development of numerous vaccines that
have proven effective against SARS-CoV-2. Several of these successful vaccines are based …

In the last few decades we have witnessed a rapid advance in the design of new
biotherapeutic products using viral particles. The current limitations of manufacturing these …

With the aim to propose innovative antimicrobial agents able to not only selectively inhibit
bacterial carbonic anhydrases (CAs) but also to be photoactivated by specific wavelengths …

Virus‐like particles‐based vaccines have been gaining interest in recent years. The
manufacturing of these particles includes their production by cell culture followed by their …

Adeno‐associated virus (AAV) vector can efficiently transduce therapeutic genes in various
tissue types with less side effects; however, owing to complex multistep processes during …

Recombinant adeno-associated virus (rAAV) is one of the most widely used viral vectors that
has been used for gene therapy to treat a variety of human diseases. As a newly developed …